Lupin has received final approval for its Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg from the United States Food and Drug Administration (USFDA) to market a generic version of US WorldMeds, LLC’s Corgard Tablets, 20 mg, 40 mg, and 80 mg.
Lupin’s Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg are the AB rated generic equivalent of US WorldMeds, LLC’s Corgard Tablets, 20 mg, 40 mg, and 80 mg. They are indicated for management of patients with angina pectoris and for the treatment of hypertension. Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately $109.8 million in the US, as per IMS MAT June 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
